One step closer to reversing liver failure

Publicly released:
Australia; International

Researchers at Peter Mac have made a key discovery in liver regeneration that may have important implications for liver cancer. Joint research between Associate Professor Andrew Cox and Professor Mark Dawson, published this week in Developmental Cell, has identified how the liver is triggered to regrow when damaged. Associate Professor Cox, Group Leader at Peter Mac said although the liver is one of the only tissues capable of regeneration, we know very little about the cues that trigger the regenerative process.

Media release

From: Peter MacCallum Cancer Centre

Researchers at Peter Mac have made a key discovery in liver regeneration that may have important implications for liver cancer.

Joint research between Associate Professor Andrew Cox and Professor Mark Dawson, published this week in Developmental Cell, has identified how the liver is triggered to regrow when damaged.

Associate Professor Cox, Group Leader at Peter Mac said although the liver is one of the only tissues capable of regeneration, we know very little about the cues that trigger the regenerative process.

“We worked collaboratively with the Dawson Lab at Peter Mac to develop a new tool that allowed us to trace gene expression during the early stages of liver regeneration,” Associate Professor Cox explained.

“We found that liver injury induces a stress response involving a factor known as Nrf2, which reprograms the metabolic state of liver cells to facilitate regeneration.”

Professor Dawson, Head of Cancer Biology and Therapeutics Program and Head of Cancer Epigenetics Laboratory at Peter Mac, said the work has important implications for the treatment of patients undergoing liver failure while also laying the groundwork for future therapies in regenerative medicine.

“This work highlights the therapeutic potential of stimulating Nrf2 to enhance regeneration in cases of liver failure,” Professor Dawson said.

“There are Nrf2 activating compounds that have already undergone clinical trials for various indications, so these treatments have the potential to be applied in the setting of acute liver failure.

“Paradoxically, the Nrf2 gene is often hyperactivated by mutations in cancer, leading to oncogenic growth. Our future studies seek to identify therapeutic strategies to inhibit Nrf2 in cancer or activate Nrf2 in the liver injury setting,” he said.

In Australia more than 6 million people suffer from liver diseases and more than 7000 die each year from chronic liver disease.

The research was published today in Developmental Cell.

In Australia more than 6 million people suffer from chronic liver disease and more than 7000 die each year from chronic liver disease.

Journal/
conference:
Developmental Cell
Research:Paper
Organisation/s: Peter MacCallum Cancer Centre
Funder: The following funded the research through fellowship, scholarship and grant support: Sir Edward Dunlop Fellowship, Cancer Council of Victoria, NHMRC Investigator Grant 1196749 and Howard Hughes Medical Institute International Research Scholarship 55008729 (M.A.D.), NHMRC Project Grant 1146558, NHMRC Investigator Grant GNT1176650, ARC Discovery Project Grant DP200102693 and Peter MacCallum Cancer Foundation (A.G.C.), Peter MacCallum Postgraduate Scholarship (V.W.T.T.), Yayasan Dayadiri Scholarship and Melbourne Research Scholarship (T.M.S.), Maddie Riewoldt’s Vision 064728 (Y.-C.C.) and Melbourne Research Scholarship (C.E.B.). The funders had no role in study design, data collection analysis, or decision to publish or preparation of the manuscript.
Media Contact/s
Contact details are only visible to registered journalists.